News Category
Regentis Biomaterials' new patent for its solvent-free manufacturing process strengthens its IP portfolio and supports scaling up production of its of...
VERAXA Biotech's collaboration with Ardigen aims to use AI to identify optimal dual-target combinations for cancer therapies, potentially reviving aba...
VERAXA Biotech's collaboration with Ardigen aims to use AI to optimize its BiTAC platform, potentially improving target validation and reducing develo...
Nanox Imaging's subsidiary signs an exclusive UK reseller agreement with Vertec Scientific for its AI bone solution HealthOST, following NICE's recomm...
Helix BioPharma strengthens its leadership with the appointment of Dr. Markus Loeffler as CMO to guide its oncology pipeline through upcoming clinical...
Quantum BioPharma reported reduced Q2 expenses and FDA clearance to start Phase 2 trials for its multiple sclerosis drug, positioning the company for ...
Regentis Biomaterials is simultaneously progressing its GelrinC cartilage repair implant through a pivotal US Phase III trial and European commercial ...
Helix BioPharma reshapes its board to align with strategic goals, appointing CEO Thomas Mehrling as director following Janusz Grabski's resignation.
Onco-Innovations is building the manufacturing and scientific foundation for its nanoparticle-encapsulated PNKP inhibitor ONC010, aiming to advance bi...
Researchers at the University of Manchester found that a small group of immune cells, previously understudied, plays a crucial role in mobilizing the ...
Quantum BioPharma reported reduced Q2 expenses and received FDA approval for its Phase 2 trial of Lucid-MS, a potential treatment for progressive mult...
Regentis Biomaterials is strategically advancing its cartilage repair product GelrinC through parallel U.S. clinical trials and European commercializa...
HeartBeam's recent progress in clinical trials, product development, and initial commercialization positions it to potentially transform heart attack ...
Lantern Pharma reported Q2 2026 results highlighting pipeline progress and the establishment of Open Medicine AI as a separate company, marking a stra...
NeOnc Technologies' NEO100 meets primary endpoint in Phase 2a for recurrent brain cancer, with survival signals and FDA alignment advancing both NEO10...
Quantum BioPharma's Lucid-MS focuses on inhibiting myelin degradation to address progression independent of relapse activity, a key driver of long-ter...
GeoVax emphasizes the potential of its MVA-based vaccine candidates and expertise to contribute to the global response against the escalating Bundibug...
Nutriband's CEO will present at the 2026 Georgia Life Sciences Summit, underscoring the company's commitment to addressing opioid abuse through its AV...
Regentis Biomaterials' new Japanese patent allowance and recent US grant protect its scalable manufacturing process for GelrinC, positioning it to mee...
Quantum BioPharma's FDA approval to advance Lucid-MS into Phase 2 trials marks a significant step toward a potential disease-modifying therapy for mul...
PX1 Research's expanded cGMP quality control and seven-stage HPLC purity verification ensure 99%+ purity for research peptides, providing batch-specif...
NanoViricides has received regulatory approval to begin a Phase II clinical trial of its oral antiviral NV-387 for Ebola in the Democratic Republic of...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth in TNBC models, providing the scientific f...
Quantum BioPharma's FDA approval to begin Phase 2 trials for Lucid-MS, a novel neuroprotective candidate for multiple sclerosis, marks a significant s...
Tonix Pharmaceuticals' Q2 revenue surged to $13.5 million, driven by TONMYA sales, signaling strong market uptake and positioning the company for cont...
Tonix Pharmaceuticals' second-quarter 2026 results show a dramatic revenue increase driven by TONMYA, highlighting the drug's commercial success and t...
Regentis Biomaterials progresses its GelrinC cartilage regeneration technology through U.S. clinical trials, FDA submission preparation, European comm...
Quantum BioPharma is progressing its two-pronged approach to neurological health, targeting multiple sclerosis with Lucid-MS and alcohol misuse with u...
Quantum BioPharma is advancing its investigational MS therapy Lucid-MS and its supplement unbuzzd, targeting neurological health through distinct mech...
VERAXA Biotech's BiTAC platform positions it in the antibody therapeutics market, where significant investments highlight the value of differentiated ...
A Spanish patient initially treated for brain cancer was found to have pork tapeworm cysts, underscoring the dangers of undercooked pork and the need ...
VERAXA Biotech's VXA-222 bispecific antibody-drug conjugate program has advanced past the discovery phase, and the company has expanded its intellectu...
A new liquid biopsy offers a simpler way to predict immunotherapy response in advanced lung cancer, potentially guiding treatment decisions and aiding...
GeoVax announces completion of manufacturing, regulatory, clinical, and preclinical milestones for its GEO-MVA mpox/smallpox vaccine, positioning it f...
Onco-Innovations is advancing an integrated cancer drug development strategy that combines PNKP-targeted DNA damage response inhibition, nanoparticle ...
Researchers at Nagoya University discovered that the ancient protein C3, when produced within tumors, can boost the effectiveness of immunotherapy, of...
VolitionRx's new Capture-Seq technology, which isolates over 99% pure circulating tumor DNA, could transform cancer detection and monitoring, addressi...
Tonix Pharmaceuticals' participation in key investor conferences underscores its commitment to advancing its CNS and immunology pipeline, particularly...
VERAXA Biotech AG progresses its VXA-222 bispecific antibody-drug conjugate into the next development stage after completing the discovery phase with ...
NeuroThera Labs has launched a Phase IIb clinical trial at Yale Child Study Center for SCI-110, a cannabinoid-based drug candidate for Tourette Syndro...
SRX Global's investment in Vistagen signals a strategic bet on neuroscience therapies and potential value unlocking, highlighting the intersection of ...
SRX Global's acquisition of a stake in Vistagen Therapeutics signals confidence in the biopharmaceutical company's potential and could lead to actions...
Quantum BioPharma's pilot MS imaging study with Massachusetts General Hospital has reached halfway enrollment, with preliminary data showing encouragi...
Biotech Labz Supply Inc has expanded its online catalog to 11 documented research peptides, providing qualified researchers with batch-specific COA do...
Oncotelic Therapeutics will present at the OTCQB Virtual Investor Conference, highlighting advancements in its clinical trials, drug delivery platform...
Tonix Pharmaceuticals received FDA feedback supporting its adaptive Phase 2 study of TNX-4800, a long-acting antibody for Lyme disease prevention, wit...
GeoVax underscores the strategic value of its MVA-based filovirus vaccine portfolio following independent research suggesting cross-reactive immune re...
Regentis Biomaterials is developing GelrinC, a cell-free hydrogel implant designed to address the significant unmet need in cartilage repair, offering...
